<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522196</url>
  </required_header>
  <id_info>
    <org_study_id>AN-SCD1122</org_study_id>
    <nct_id>NCT01522196</nct_id>
  </id_info>
  <brief_title>A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.</brief_title>
  <acronym>IMPACTS-2</acronym>
  <official_title>A Randomized, Double-blind, Placebo-Controlled Study With Varespladib Infusion (A-001) in Subjects With Sickle Cell Disease and Vaso-Occlusive Crisis for the Prevention of Acute Chest Syndrome At-Risk Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anthera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of A 001 infusion in preventing
      acute chest syndrome in sickle cell disease (SCD) subjects with vaso-occlusive crisis, fever,
      and elevated serum C-reactive protein (CRP).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    change in company plans
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with the combination of vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).</measure>
    <time_frame>Various time points up to Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of A 001 therapy when administered as a 48-hour continuous infusion to SCD subjects at-risk for acute chest syndrome.</measure>
    <time_frame>Various time points up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of A-001 treatment on sPLA2 levels and CRP.</measure>
    <time_frame>Various time points up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of A-001 treatment on the signs and symptoms of vaso-occlusive crisis.</measure>
    <time_frame>Various time points up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of A-001 treatment on opioid use for pain in the treatment of vaso-occlusive crisis.</measure>
    <time_frame>Various time points up to Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Vaso-occlusive Crisis</condition>
  <arm_group>
    <arm_group_label>Varespladib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>48 hour continuous infusion delivered intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>48 hour continuous infusion delivered intravenously (IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varespladib</intervention_name>
    <description>48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.</description>
    <arm_group_label>Varespladib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Normal Saline)</intervention_name>
    <description>48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genotypes Hb SS, Hb SC, sickle β°-thalassemia, sickle β+ -thalassemia

          -  Pain consistent with vaso-occlusive crisis (clinical judgment) and not attributable to
             other causes

          -  Serum CRP ≥5.0 mg/L at time of screening

          -  Fever defined as oral temperature ≥38.0°C at time of screening

          -  Age ≥5 years

        Exclusion Criteria:

          -  New or suspected new pulmonary infiltrate diagnosed by chest radiography

          -  Females who are nursing, pregnant or intend to become pregnant

          -  Renal dysfunction defined as a creatinine level &gt;1.2 mg/dL for subjects aged 18 or
             less or a creatinine level &gt;1.5 mg/dL for subjects over the age of 18

          -  Hepatic dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase
             [AST] &gt;3 × upper limit of normal)

          -  Acute neurologic dysfunction

          -  Any medical condition for which transfusion may be needed imminently, and/or
             hemoglobin &lt;5 g/dL

          -  Red blood cell transfusion within 30 days prior to screening

          -  Parenteral or oral corticosteroid therapy (inhaled steroids acceptable) within 7 days
             prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator Site 101</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2012</study_first_posted>
  <disposition_first_submitted>January 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 4, 2014</disposition_first_posted>
  <last_update_submitted>January 30, 2014</last_update_submitted>
  <last_update_submitted_qc>January 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varespladib methyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

